Radiation Therapy and Cardiac Enzymes
|ClinicalTrials.gov Identifier: NCT00777751|
Recruitment Status : Completed
First Posted : October 22, 2008
Last Update Posted : January 10, 2018
|Condition or disease|
Cardiac biomarkers are proteins made by the heart. When cardiac biomarkers are above normal levels, there may be damage to the heart. The relationship between cardiac biomarkers and radiation therapy has not been well studied. Learning more about this relationship may lead to better ways to check the heart during radiation therapy. How cardiac biomarkers can play a role in predicting future heart problems during radiation therapy will also be studied.
If you agree to take part in this study, blood (about 1 teaspoon) will be drawn to measure certain cardiac biomarkers up to 2 days before radiation therapy, following the first treatment of radiation, within 2 days of finishing radiation therapy, and about 1 to 2 months after completion of radiation therapy. Once the blood testing is completed, any leftover blood samples will be destroyed.
You will also have electrocardiograms (ECGs -- tests that measure the electrical activity of the heart) at the same time points as the blood draws.
Length of Study:
You will be off study after the last blood draw and ECG.
This is an investigational study. Up to 30 patients will be enrolled in this study. All will be enrolled at M. D. Anderson.
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Radiation Therapy and Cardiac Biomarkers|
|Actual Study Start Date :||October 6, 2008|
|Primary Completion Date :||November 21, 2016|
|Study Completion Date :||November 21, 2016|
- Elevation in cardiac biomarkers by measuring cardiac troponins (troponin T and troponin I), BNP, and CK-MB. [ Time Frame: 4 Time Points: within 1 week prior to radiation therapy (RT), within 1-3 days of RT completion, and at 1 and 3 months after completion of RT. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00777751
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||David Grosshans, MD||M.D. Anderson Cancer Center|